Literature DB >> 16840914

[Hepatitis C and diabetes mellitus: effect of diabetes on the course of the liver disease].

N Kabbaj1, I Errabih, M Guédira, H El Atmani, K Benabed, Z Al Hamany, M Mohammadi, A Benaïssa.   

Abstract

UNLABELLED: The prevalence of diabetes mellitus is higher in chronic hepatitis C than in hepatitis B, even without cirrhosis.
OBJECTIVE: To study the host, specific viral factors associated with diabetes mellitus and the influence of diabetes mellitus on the intensity of steatosis and the severity of fibrosis.
MATERIAL AND METHODS: The following data were collected in a cohort of 1249 patients with chronic hepatitis C established between December 1991 and June 2004: age, gender, body mass index (BMI). None of the patients were under treatment for their liver disease. Serum transaminase level and hepatitis C serology with search for viral RNA, viral load and genotype were obtained. The Metavir score, iron overload using the Perls score (0-4) and steatosis class (0-3) were determined on liver biopsies.
RESULTS: Mean patient age was 52.5+/-10 years (56% male). Mean BMI was 24.6+/-24 kg/m2. Forty-three patients (17.2%) presented diabetes mellitus. The mean duration of their diabetes was 8.9 years. Genotype 1 predominated (60.4%) and mean viral load was 7.7x10(6) eq.v/ml. Steatosis was present in 69.7% of the diabetic patients versus 17% of the non-diabetic patients. Grade 2 fibrosis (F2) was observed in 32.5% of diabetic patients versus 29% in non-diabetic patients and F3, F4 in 73% of the diabetic patients versus 57% of the non-diabetic patients. Comparison between diabetic and non-diabetic patients demonstrated an absence of statistically significant difference (at 5%) between the groups for gender, viral load and genotype. Diabetic persons were older (58.7 years against 51 years) and liver biopsy revealed steatosis and fibrosis (F3, F4) more often in diabetic patients (69.7% versus 49.5%).
CONCLUSION: These findings suggest that steatosis could favor progression of fibrosis in diabetics with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840914     DOI: 10.1016/s0003-4266(06)72591-4

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  2 in total

Review 1.  Endocrine disorders associated with hepatitis C virus chronic infection.

Authors:  Michele Colaci; Lorenzo Malatino; Alessandro Antonelli; Poupak Fallahi; Dilia Giuggioli; Clodoveo Ferri
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

2.  Rosiglitazone protects diabetic rats from liver destruction.

Authors:  Y-L Lu; T-T Ye; Y Chen; J Yu; L-J Zhao; N-J Wang; B-R Jiang; J Qiao; L-Z Yang
Journal:  J Endocrinol Invest       Date:  2011-07-25       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.